Innovent Biologics (SEHK:1801) Stock Could Be 49% Below Fair Value After ADA Pipeline Update

Simply Wall St.06-22

Innovent Biologics (SEHK:1801) drew extra attention after presenting fresh clinical and preclinical data on its metabolic and obesity drug pipeline at the 2026 American Diabetes Association Scientific...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645019635?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-22 02:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645019635","market":"nz","top_or_hot":-1,"title":"Innovent Biologics (SEHK:1801) Stock Could Be 49% Below Fair Value After ADA Pipeline Update","media":"Simply Wall St.","content":"<div>\n<p>Innovent Biologics (SEHK:1801) drew extra attention after presenting fresh clinical and preclinical data on its metabolic and obesity drug pipeline at the 2026 American Diabetes Association Scientific...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-could-be-49-below-fair-val\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics (SEHK:1801) Stock Could Be 49% Below Fair Value After ADA Pipeline Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics (SEHK:1801) Stock Could Be 49% Below Fair Value After ADA Pipeline Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-22 02:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-could-be-49-below-fair-val><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innovent Biologics (SEHK:1801) drew extra attention after presenting fresh clinical and preclinical data on its metabolic and obesity drug pipeline at the 2026 American Diabetes Association Scientific...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-could-be-49-below-fair-val\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242644610.SGD","symbol_name":"Fidelity China Innovation A-ACC-SGD","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-could-be-49-below-fair-val","article_id":"2645019635","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-stock-could-be-49-below-fair-val","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645019635","pubTimestamp":1782066162,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Innovent Biologics (SEHK:1801) drew extra attention after presenting fresh clinical and preclinical data on its metabolic and obesity drug pipeline at the 2026 American Diabetes Association Scientific Sessions, highlighting several GLP-1 and amylin candidates.\nSee our latest analysis for Innovent Biologics.\nThe recent clinical updates appear to have come at a time when momentum in Innovent Biologics has been easing. The share price is at HK$76.15 and the 30 day share price return is down...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1589":"北水核心资产","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01801":"信达生物","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1161":"生物科技","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1583":"高瓴概念","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC"},"translate_title":"ADA管道更新后，信达生物(SEHK：1801)股价可能比公允价值低49%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"01801":0.9},"content_text":"Innovent Biologics (SEHK:1801) drew extra attention after presenting fresh clinical and preclinical data on its metabolic and obesity drug pipeline at the 2026 American Diabetes Association Scientific Sessions, highlighting several GLP-1 and amylin candidates. See our latest analysis for Innovent Biologics. The recent clinical updates appear to have come at a time when momentum in Innovent Biologics has been easing. The share price is at HK$76.15 and the 30 day share price return is down 7.75%, while the 3 year total shareholder return of 150.08% still points to a strong longer term journey. If this obesity and diabetes pipeline has caught your attention, it could be a good moment to see what else is developing in healthcare, starting with 131 healthcare AI stocks With Innovent Biologics now trading at HK$76.15 alongside an intrinsic value estimate and analyst target that both sit higher, you have to ask: is this recent weakness a chance to get in, or is the market already pricing in future growth? AdvertisementPreferred P/E of 140.5x: Is it justified? On the numbers, Innovent Biologics looks expensive on earnings, with a P/E of 140.5x compared to an estimated fair P/E of 29.2x, and a last close of HK$76.15 that sits well below some intrinsic value estimates. The P/E multiple tells you how much investors are paying for each unit of current earnings, which matters a lot for a company that only recently became profitable. With Innovent Biologics, the data points to the market paying a high price for today’s earnings while models that look at future cash flows and fair ratios suggest a lower multiple could eventually be more in line with fundamentals. Against the wider Asian Biotechs industry average P/E of 29.1x and a peer average of 30x, Innovent Biologics is priced at a very large premium. Compared to the estimated fair P/E of 29.2x, the gap is even clearer, which is the level some models suggest the market could gravitate toward if expectations and reality move closer together. Explore the SWS fair ratio for Innovent Biologics Result: Price-to-earnings of 140.5x (OVERVALUED) However, the premium P/E on Innovent Biologics could be sensitive to any setback in its drug pipeline or to delays in converting research into revenue growth. Find out about the key risks to this Innovent Biologics narrative. Another View: What the SWS DCF Model Says About Innovent Biologics While the P/E of 140.5x makes Innovent Biologics look expensive on earnings, the SWS DCF model points the other way. It presents an estimated future cash flow value of HK$149.24 versus the current HK$76.15, suggesting the stock is trading well below that cash flow based estimate. Look into how the SWS DCF model arrives at its fair value. 1801 Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innovent Biologics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 213 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps After weighing both the premium P/E and the DCF upside around Innovent Biologics, it comes down to how you balance its risks against its potential rewards. Act while the information is fresh and shape your own view by reviewing the 4 key rewards and 1 important warning sign Looking for more investment ideas beyond Innovent Biologics? If the Innovent Biologics story has sharpened your focus, now is the time to widen your watchlist and find other opportunities that fit your approach.  Target potential value opportunities by scanning companies that appear mispriced on quality and fundamentals through the 213 high quality undervalued stocks. Strengthen your core holdings by reviewing companies that feature resilient finances and prudent balance sheets in the solid balance sheet and fundamentals stocks screener (415 results). Get ahead of the crowd by spotting lesser known companies with strong underlying metrics using the screener containing 499 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645019635","isCrawlerRequest":true}